Skip to main content
SLBTSL Science Holding LimitedSell4.6·$1.21
SellModerate Confidence
Investment thesis

SL Science Holding shows weak fundamental quality (0/9 Piotroski, no moat) and a confirmed falling-knife downtrend (death cross, RSI 39, bearish MACD), and the engine's own asymmetry check models 0% upside even though a resistance-based price target implies 137% upside — a conflict the data does not resolve, keeping the stock flagged for exit.

Thesis pillars

  • Weak Quality No Moat→Stable
  • Confirmed Falling Knife Downtrend↓Deteriorating
  • Upside Estimate Conflict→Stable
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 5, 2026

Full reasoning →

Open full analysis

SL Science Holding Limited (SLBT) Stock Analysis

SellVALUE-TRAP 2/5ValueQualityShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $1.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.6/10.

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells,... Read more

$1.21+41.3% A.UpsideScore 4.6/10#213 of 241 Biotechnology
QualityF-score5 / 9FCF yield—
Stop $1.13Resistance target $1.71A.R:R 0.0:1

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $1.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.6/10. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.6/10, moderate confidence.

Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29

Recent Developments — SL Science Holding Limited

Generated 2026-10-29T11:48:40Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Positive insider activity
Risks
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
Weak overall score: 4.6/10
Weak growth

Key Metrics

P/E (TTM)—
P/E (Fwd)—
Mkt Cap$679M
EV/EBITDA-0.6
Profit Mgn-72.5%
ROE—
Rev Growth-7.6%
Beta—
DividendNone
Rating analysts—

Quality Signals

Piotroski F5/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.6
Declining revenue: -8%
Low model confidence on this dimension (33%).

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Ma Position
1.0
Rsi
3.0
Macd
6.1
Obv
6.2
Capitulation risk (RSI 22, below 200MA)Below 200-MA, MA slope -17.9%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.5
Growth Rank
3.2
Value Rank
5.0
GatesMomentum 3.3<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
22 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $1.02Resistance $1.75

Price Targets

$1
$2
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeRisk-Off

Risk Alerts

! momentum at 3.3 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

We could not retrieve earnings history for SLBT.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SLBT stock a buy right now?

Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $1.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.6/10. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $1.13. Score 4.6/10, moderate confidence.

What is the SLBT stock price target?

Resistance target: $1.71 (+41.3% upside). Prior stop was $1.13. Stop-loss: $1.13.

What are the risks of investing in SLBT?

V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.6/10; Weak growth.

Is SLBT overvalued or undervalued?

SL Science Holding Limited trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Sell.

0
What does SL Science Holding Limited do?SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL...

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Related stocks: CRMD (CorMedix Inc.) · HRMY (Harmony Biosciences Holdings, I) · ZVRA (Zevra Therapeutics, Inc.) · AUPH (Aurinia Pharmaceuticals Inc) · PHAT (Phathom Pharmaceuticals, Inc.)
Home › Stocks › SLBT

Latest news

Latest News

Fiscal.ai1d agoEarnings
Benzinga3d agoEarnings
Benzinga31d ago
Benzinga31d ago
Benzinga49d ago
Benzinga56d ago
Benzinga56d ago
Benzinga56d ago
Benzinga63d agoFda Decision
Benzinga63d agoFda Decision
Benzinga79d agoProduct
Benzinga87d ago
Benzinga104d agoProduct
Benzinga107d ago
Benzinga111d agoFda Decision
Benzinga115d ago
Benzinga115d ago
Benzinga119d ago
Benzinga119d ago
Benzinga120d ago